Washington, DC – The District of Columbia’s Department of Employment Services reported today that the seasonally adjusted preliminary unemployment rate was 5.1 percent in June 2023; unchanged from the revised May 2023 rate of 5.1 percent. The District’s …
TORONTO, July 21, 2023 (GLOBE NEWSWIRE) -- Hemlo Explorers Inc. (the “Company”) (TSXV: HMLO) is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the “Offering”). In the final …
Published: Jul 21, 2023 SACRAMENTO – Governor Gavin Newsom today announced that he has signed the following bills: AB 72 by Assemblymember Tasha Boerner (D-Encinitas) – Coastal resources: research: landslides and erosion: early warning system. AB 87 by …
Published: Jul 21, 2023 SACRAMENTO – Governor Gavin Newsom today announced that he has signed the following bills: AB 72 by Assemblymember Tasha Boerner (D-Encinitas) – Coastal resources: research: landslides and erosion: early warning system. AB 87 by …
The European Medicines Agency has recommended the refusal of the conditional marketing authorisation for Krazati, a medicine intended for treating advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation. The Agency issued its opinion on 20 July …
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Keytruda. The marketing authorisation holder for this …
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Bylvay. The marketing authorisation holder for this medicinal …
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Yesafili, intended for the treatment of neovascular (wet) age-related …
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Tyenne, intended for the treatment of rheumatoid arthritis (RA), …
Summary of opinion: Ervebo,Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP, live), 20/07/2023, Positive
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Enrylaze, intended for the treatment of acute lymphoblastic leukaemia ( …
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Inaqovi, intended for the treatment of acute myeloid leukaemia (AML …
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Olumiant to include the treatment of juvenile idiopathic …
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional1 marketing authorisation for the medicinal product Talvey2, intended for the treatment of multiple myeloma. …
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Opdivo. The marketing authorisation holder for this medicinal …
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional1 marketing authorisation for the medicinal product Tepkinly2, intended for the treatment of diffuse large B‑ …
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Spikevax. The marketing authorisation holder for this …
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Abrysvo, intended for the prevention of lower respiratory tract (LRT) …
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Tevimbra1 intended for the treatment of oesophageal squamous cell …
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Apretude, intended for prevention of sexually acquired HIV-1 in …
05 days 14:07:45
